A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers

Background Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays is the rather long test‐turnaround times. A particle enhanced turbidimetric immunoassays (PETIA) for fecal calprotectin would...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical laboratory analysis 2017-07, Vol.31 (4), p.e22061-n/a
Hauptverfasser: Nilsen, Tom, Sunde, Kathrin, Hansson, Lars‐Olof, Havelka, Aleksandra Mandic, Larsson, Anders
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays is the rather long test‐turnaround times. A particle enhanced turbidimetric immunoassays (PETIA) for fecal calprotectin would reduce test‐turnaround times and would permit more laboratories to perform the measurements. The aim of this study was to evaluate a new feces calprotectin PETIA. Method Using routine fecal samples the feces calprotectin PETIA was validated on two chemistry analyzers, Mindray BS‐380 and Cobas 501. Results The assay is linear in the range 11–2000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10 000–15 000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3%–8% in the 50–100 μg/g range. Conclusion The fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS‐380 or Cobas 501 clinical chemistry analyzers. The test results are commutable with Bühlmann fecal MRP8/14 ELISA.
ISSN:0887-8013
1098-2825
1098-2825
DOI:10.1002/jcla.22061